An Incisive, In-depth Analysis on the Connected Drug Delivery Devices Market
This study offers a comprehensive, 360 degree analysis on the Connected Drug Delivery Devices market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Connected Drug Delivery Devices market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
The growing healthcare expenditure provides significant opportunities to hospitals and companies in generating higher revenues. According to the Organization for Economic Cooperation and Development (OECD), the spending on healthcare is estimated to reach US$ 10 trillion by 2020. The healthcare spending in most of the European countries is growing faster than their GDP. According to the U.S. government’s center for Medicare and Medicaid Services (CMS) the healthcare expenditure has risen approximately by 7% and is expected to cross US$ 2 trillion. The Congressional Budget Office states that if the growth in healthcare spending continues at this rate, the CMS spending and private health cost would increase approximately to 25% of the GDP.
For minimizing the healthcare costs and improve the quality of life, countries across the world are seeking to shift the place of care from healthcare facilities to wherever the patients happen to be during their normal day. Half of all the healthcare will take place outside the healthcare facilities within the decade. In many cases, the future of healthcare will be environments such as the home, workplace, school, café, or gym, with the patients responsible for the administration of their therapy. With the typical frequency for a self-injectable biologic ranging from one week to every month or quarter, devices that contain and deliver a drug must be highly intuitive. This trend will continue to accelerate over the next decade, as payers and providers will seek greater access to real-time, cloud-based data that can accurately assess how patients with a chronic disease adhere to their assigned drug regime.
North America will take the lead in the market in the long run with the maximum adoption
Significant focus on shifting to value-based reimbursement model are likely to reduce healthcare costs, which is over 17% of total GDP and health services financing sources witnessing an increase from private sources and decrease in public subsidies is expected to have a major impact on the
Health service providers increasingly collaborating with customers are expected to demonstrate clinical and financial benefit of services and the penetration of artificial intelligence technologies and big data analytics in health technologies, especially for real-time decision making to manage chronic diseases will pave way for future prospects for the market in North America in the near future. Vendors achieving economies of scale by leveraging large customer base and maintaining leading market position are expected to take the market forward in the long run. High geriatric population in the U.S. is anticipated to boost the demand for home healthcare and patient monitoring devices and services in the region and thus, augur well for the market growth in the region.
Western Europe is expected to closely follow North America in the coming years
Countries such as France, Germany, Italy, and Spain are expected to witness fluctuating demand for connected drug delivery devices in the coming years. France has high potential market but adoption of mobile health is average showing more reluctant to embrace digitalization of healthcare. The implementation of mobile health and related connected drug delivery devices is expected to present considerable challenges, including technological barriers, organizational challenges, confidentiality concerns and unplanned aftereffects. German consumers’ willingness to invest in their well-being and fast data networks is providing fertile ground for mHealth and connected drug delivery devices market growth. Health insurers in Germany have not yet introduced comprehensive reimbursement for m-health applications and connected drug delivery devices, any such strategic changes to acquire larger set of customer will be focused on younger, healthy consumers willing to pay for these services. This might adversely impact the market growth in the region.
Global Healthcare Sector Outlook in Light of the Global Connected Drug Delivery Devices Market
Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.
A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.
Parent Indicators Healthcare
-
Current expenditure on health, % of gross domestic product
-
Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs)
-
Annual growth rate of current expenditure on health, per capita, in real terms
-
Out-of-pocket expenditure, % of current expenditure on health
-
Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs)
-
Physicians, Density per 1000 population (head counts)
-
Nurses, Density per 1000 population (head counts)
-
Total hospital beds, per 1000 population
-
Curative (acute) care beds, per 1000 population
-
Medical technology, Magnetic Resonance Imaging units, total, per million population
-
Medical technology, Computed Tomography scanners, total, per million population
Research Methodology
FMI utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, number of procedures and capital equipment install base to obtain precise market estimations and insights on various medical devices and medical technology. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.
Secondary research is used at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product offerings, usage pattern as per disease indications, product installed base in target healthcare facilities, life span of a device, reimbursement scenario, adoption rate and future impact of new technologies.
Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.
Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, and supply-side providers of medical devices who provide valuable insights on trends, key treatment patterns, adoption rate, and purchasing pattern, technological development of medical devices, patient education, effectiveness of manufacturers and important strategies, pricing and competitive dynamics.
Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.
On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at tier level based on their revenues, product portfolio and presence.
Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.
Standard Report Structure
-
Executive Summary
-
Market Definition
-
Macro-economic analysis
-
Parent Market Analysis
-
Market Overview
-
Forecast Factors
-
Segmental Analysis and Forecast
-
Regional Analysis
-
Competition Analysis
Market Taxonomy
The global connected drug delivery devices market has been segmented into:
|
Region |
End User |
Product Type |
Technology |
Application |
|---|---|---|---|---|
|
|
|
|
|
COVID -19 : Impact Analysis
Request the coronavirus impact analysis across industries and markets
Request Covid -19 ImpactGet in touch
Our Clients
CASE STUDIES
See how our work makes an impact.
At FMI, we design strategies that are adaptive, impactful, and implementable.